At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 209 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 1.4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia
In Brief
A Phase 4 clinical trial evaluating Atomoxetine and Placebo for Attention Deficit Hyperactivity Disorder and Dyslexia. Completed, enrolled 209 participants across 16 sites.
Detailed Summary
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder, Dyslexia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionNov 2010
Study CompletionFeb 2011
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.4 years ago
Interventions
Atomoxetinedrug
Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
Placebodrug
oral, daily, for 16 weeks